Leadership & Pay ·
Cingulate Inc. announced that its wholly owned subsidiary, Cingulate Therapeutics LLC, amended the employment…
CINGCingulate Inc.
Cingulate Inc. announced that its wholly owned subsidiary, Cingulate Therapeutics LLC, amended the employment agreement for Matthew N. Brams, Executive Vice President and Chief Medical Officer,<pad> extending his full-time employment trial period from June 30, 2026, to September 30, 2026. Additionally, the company<pad> announced its selection for membership in the Russell 3000E Index. Cingulate Inc. is a biotechnology company.